About wpteam

This author has not yet filled in any details.
So far wpteam has created 29 blog entries.

June 2020

Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Patients with Metastatic or Unresectable Melanoma Who Have Progressed on Anti–PD-1/L1 Therapy

By |2020-06-22T14:22:50+00:00June 22nd, 2020|

Linnaeus Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma who have progressed on or after anti–programmed cell death receptor or ligand (anti–PD-1/L1) therapy. Haddonfield NJ, June 18, [...]

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Pancreatic Cancer Data in Cellular and Molecular Gastroenterology and Hepatology

By |2020-06-12T15:15:34+00:00June 10th, 2020|

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Pancreatic Cancer Data in Cellular and Molecular Gastroenterology and Hepatology Haddonfield NJ, June 10, 2020 -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that its [...]

October 2019

Linnaeus Therapeutics Announces First Patient Dosed in Its Phase 1/2 Clinical Trial of LNS8801 in Patients with Advanced Cancer

By |2019-10-30T12:56:50+00:00October 30th, 2019|

Linnaeus Therapeutics Announces First Patient Dosed in Its Phase 1/2 Clinical Trial of LNS8801 in Patients with Advanced Cancer Company Commences First-in-Human Study at Multiple Academic Sites in United States Haddonfield NJ,October 29, 2019--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development [...]

September 2019

Linnaeus Therapeutics Announces FDA Clearance of Investigational New Drug Application for LNS8801

By |2019-10-30T12:56:21+00:00September 24th, 2019|

Linnaeus Therapeutics Announces FDA Clearance of Investigational New Drug Application for LNS8801 Haddonfield NJ, September 24, 2019--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held, clinical-stage biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that the U.S. Food and Drug [...]

Linnaeus Therapeutics Closes $12 Million Series B Financing

By |2019-09-17T14:41:06+00:00September 17th, 2019|

Linnaeus Therapeutics Closes $12 Million Series B Financing Linnaeus Therapeutics, Inc. ("Linnaeus"), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that it has closed a $12 million series B financing. Kairos Ventures, of Beverly Hills, California, [...]

Linnaeus Therapeutics Scientific Cofounder Presents Preclinical Pancreatic Cancer Data at AACR Pancreas Cancer Meeting

By |2019-09-13T19:22:00+00:00September 11th, 2019|

Linnaeus Therapeutics Scientific Cofounder Presents Preclinical Pancreatic Cancer Data at AACR Pancreas Cancer Meeting Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that its scientific cofounder, Todd Ridky, MD, PhD, Assistant Professor [...]

February 2019

Linnaeus Therapeutics Awarded $2,000,000 Phase 2 SBIR

By |2019-03-19T00:38:19+00:00February 21st, 2019|

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced it has been awarded a Phase 2 Small Business Innovation Research (“SBIR”) Award by the National Cancer Institute (“NCI”) of the National Institute for Health (“NIH”).

September 2018

Linnaeus Therapeutics Appoints Tina Garyantes, Ph.D., to Senior Vice President of Research and Development

By |2019-03-12T17:54:25+00:00September 1st, 2018|

Linnaeus Therapeutics Appoints Tina Garyantes, Ph.D., to Senior Vice President of Research and Development Haddonfield NJ, September 1, 2018--Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced the appointment of Tina Garyantes, Ph.D., [...]

August 2018

Linnaeus Therapeutics Closes $4.4 Million Series A Financing

By |2019-03-14T13:44:01+00:00August 27th, 2018|

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that it has closed a $4.4 million series A financing. Kairos Ventures, of Beverly Hills, California, led the financing with significant participation from the University of Pennsylvania, Linnaeus CEO, Patrick Mooney, and Linnaeus SVP, R&D, Tina Garyantes.

January 2018

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Melanoma Data

By |2019-03-13T12:43:06+00:00January 26th, 2018|

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced that preclinical data from studies conducted at the University of Pennsylvania by its scientific founders was published in the journal eLife.